Phase 1 Multiple Sclerosis Trial, Recruiting NCT05832515 Sponsor: St. Petersburg State Pavlov Medical University Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 1 Multiple Sclerosis Trial, Recruiting

NCT05832515
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years of age
  • People with multiple sclerosis (MS) who score between 1.0 and 6.5 on a standard MS disability scale called the EDSS
  • People who have had an autoimmune disease formally diagnosed and confirmed during previous treatment
  • People whose disease has been getting worse over the last 6 months despite taking first- or second-line medications
  • People for whom standard disease-modifying treatments have not worked, are not available, or could not be tolerated
  • People who have had a relapse after a previous stem cell transplant (AHSCT)
  • People without serious other medical conditions alongside their main diagnosis
  • People whose heart is pumping effectively, with a left ventricular ejection fraction above 50% (a measure of how well the heart pumps blood)
  • People who score above 30% on the Karnofsky Performance Scale, which measures general ability to carry out daily activities
  • People who are able to swallow and take tablets or capsules by mouth
  • People with a life expectancy of more than one month
  • People who have signed an informed consent form, either personally or through a legal representative

Who may not be able to join:

  • People with moderate or serious heart problems, or a heart pumping score at or below 50%
  • People with moderate or serious reduced lung function, based on specific breathing test results falling below 70% of what is expected
  • People experiencing significant breathing difficulties (above a mild level)
  • People with serious liver problems, as shown by certain liver-related blood test results being well above normal ranges
  • People with serious kidney problems, including a kidney filtration rate below 60 mL/min
  • People who have an uncontrolled bacterial or fungal infection at the time of joining the trial
  • People who need medication to maintain their blood pressure at the time of joining the trial
  • People who score below 30% on the Karnofsky Performance Scale
  • People who are pregnant
  • People with a physical or mental health condition that prevents them from being able to sign an informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ivan S Moiseev, Pavlov First Saint Petersburg State Medical University

Phone: +79118167559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
St. Petersburg State Pavlov Medical University
Registry
ClinicalTrials.gov
Start date
1 October 2020
Est. completion
1 October 2025

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Multiple sclerosis progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov